Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors (NRT-01)
Single Center Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) Combined With Programmed Cell Death-1（PD-1） Inhibitor in the Treatment of Chinese Patients With Advanced Refractory Solid Tumors
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A PHASE1/PHASE2 clinical study on Advanced Malignant Solid Tumor, this trial is ongoing. The trial is conducted by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and has accumulated 7 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
For direct contact, visit the study record on ClinicalTrials.gov .